Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development.
about
Selection of high-level resistance to human immunodeficiency virus type 1 protease inhibitorsInhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agentContribution of the 80s loop of HIV-1 protease to the multidrug-resistance mechanism: crystallographic study of MDR769 HIV-1 protease variantsThe higher barrier of darunavir and tipranavir resistance for HIV-1 proteaseCrystal structures of multidrug-resistant HIV-1 protease in complex with two potent anti-malarial compoundsA mutation in human immunodeficiency virus type 1 protease, N88S, that causes in vitro hypersensitivity to amprenavirACTG (AIDS Clinical Trials Group) 384: a strategy trial comparing consecutive treatments for HIV-1In vitro HIV-1 evolution in response to triple reverse transcriptase inhibitors & in silico phenotypic analysisConstruction of a human immunodeficiency virus type 1 (HIV-1) library containing random combinations of amino acid substitutions in the HIV-1 protease due to resistance by protease inhibitors.Genetic selection for dissociative inhibitors of designated protein-protein interactions.An albumin-conjugated peptide exhibits potent anti-HIV activity and long in vivo half-lifeHigher Desolvation Energy Reduces Molecular Recognition in Multi-Drug Resistant HIV-1 ProteasePolymorphism of the human immunodeficiency virus type 2 (HIV-2) protease gene and selection of drug resistance mutations in HIV-2-infected patients treated with protease inhibitors.Low level of cross-resistance to amprenavir (141W94) in samples from patients pretreated with other protease inhibitors.A novel assay allows genotyping of the latent reservoir for human immunodeficiency virus type 1 in the resting CD4+ T cells of viremic patients.Salvage treatment against human immunodeficiency virus.Genotypic testing for human immunodeficiency virus type 1 drug resistance.Rapid and simple phenotypic assay for drug susceptibility of human immunodeficiency virus type 1 using CCR5-expressing HeLa/CD4(+) cell clone 1-10 (MAGIC-5)Diversity and complexity of HIV-1 drug resistance: a bioinformatics approach to predicting phenotype from genotype.Effects of HIV-1 protease on cellular functions and their potential applications in antiretroviral therapy.Investigation of Super Learner Methodology on HIV-1 Small Sample: Application on Jaguar Trial Data.Identification of a small-molecule inhibitor of HIV-1 assembly that targets the phosphatidylinositol (4,5)-bisphosphate binding site of the HIV-1 matrix protein.A multi-drug resistant HIV-1 protease is resistant to the dimerization inhibitory activity of TLF-PafF.Design, synthesis and evaluation of a potent substrate analog inhibitor identified by scanning Ala/Phe mutagenesis, mimicking substrate co-evolution, against multidrug-resistant HIV-1 protease.P1 and P1' para-fluoro phenyl groups show enhanced binding and favorable predicted pharmacological properties: structure-based virtual screening of extended lopinavir analogs against multi-drug resistant HIV-1 protease.Function-based mutation-resistant synthetic signaling device activated by HIV-1 proteolysisPersistence versus reversion of 3TC resistance in HIV-1 determine the rate of emergence of NVP resistance.Crystal structures of a multidrug-resistant human immunodeficiency virus type 1 protease reveal an expanded active-site cavity.Discovery of a small-molecule antiviral targeting the HIV-1 matrix protein.Antiretroviral drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase increase template-switching frequency.The Genetic Basis of HIV-1 Resistance to Reverse Transcriptase and Protease Inhibitors.Reverse transcriptase inhibitors as potential colorectal microbicides.Novel recombinant virus assay for measuring susceptibility of human immunodeficiency virus type 1 group M subtypes to clinically approved drugs.HIV Maintains an Evolving and Dispersed Population in Multiple Tissues during Suppressive Combined Antiretroviral Therapy in Individuals with Cancer.In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques.Mechanism of HIV antiretroviral drugs progress toward drug resistance.Correlating conformational shift induction with altered inhibitor potency in a multidrug resistant HIV-1 protease variant.In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.The use of efavirenz as a part of late rescue antiretroviral treatment.Resistance profiles of cyclic and linear inhibitors of HIV-1 protease.
P2860
Q24554340-82EBF570-852E-4FEC-ABA4-B891B9C48678Q24656023-3C6CE24C-5C1D-44EC-94E7-FAA35C02B850Q27668148-AE374F6F-AEB0-460F-A09A-AFDEBB51337BQ27672193-16CF5A39-8757-4E6E-A7E8-D10FC7A75955Q27678305-01DE4CF5-394D-4313-BA8C-DE98463ECB0DQ28344112-63BDC57C-A0A7-4A6B-BC3B-E831023F61FBQ28362780-3FEDBBE9-6428-49D6-8FCC-ED6993E634A1Q28486262-3FD8B1EF-3BCF-433B-8A16-5C259B316F72Q30818137-1FB94780-9CBA-412A-B0A7-2FD5F5E719C2Q31801167-8156694C-2881-4255-8A8A-F1F8079CB311Q33559066-49192F7C-ED2E-4953-80B3-CF060ECC0D69Q33570368-958575AC-732E-4AD9-8B8F-1D1C7AF9F1B1Q33593237-76E0B907-E5A2-4827-A70D-E230D10E26A3Q33595278-8D91B742-D4DF-48C1-BB0C-FCDD42D48873Q33724247-513188BC-5FC2-41F3-9C94-7A6DFD5BEA8BQ33730185-86BCDF0B-CE49-4A70-8EAB-B3F0D82B40AFQ33906239-82523C49-E233-45D9-A625-9237D4510AE8Q33981401-275ABB0C-C58D-4AEB-BA1A-94A3613B404AQ34032267-50F2157B-588A-48E6-9C47-73FCFE06497EQ34033572-BEF8266E-6B1E-49BB-9DAF-23318E9FF936Q34253401-8078A3AC-AF98-4EDE-A8F2-B6C1B7E0D7C1Q34567234-76747736-2A91-41EC-9F69-2796F11A1833Q34872621-51063000-2A15-4A47-A0D7-527FFECFA4C5Q34885997-AE8BEAC3-57DF-49B7-8136-7472BF4CBA5DQ35057007-CBE7F8DD-4CA7-45EA-BB48-46FE90AA18FAQ35804143-2F51DC20-12BB-498F-A5FF-56EF0301A136Q36246775-9922464A-045C-4F24-B37E-52A4A098DCBAQ36529238-C8BB723C-218C-4D2C-AAFA-30EE1321579DQ36569418-28923837-BA52-4A83-ABE9-DDEA4D210A1FQ36684283-2A851D7C-2B52-4BDC-9E5D-8C96C663DA6DQ37018369-8D3D7719-4FE9-40E7-BE2B-FF920C77EB22Q37190754-48CD3E68-B8CE-4201-AC3C-4E4052914773Q37256312-D35FF9D1-C6B6-4DDB-AFDD-19B07EAAD188Q37300442-4AC02B4F-EEAA-40AF-AAF7-0EED204EDCEEQ37682768-FD5A1E12-DEAD-4C3D-9EA8-40C89536DC97Q37961181-59D60C62-9B70-49E5-B9DF-3B1D634CEBFCQ38647981-DCE3CAEE-F7C5-430D-83B5-A47E40DE247FQ42111140-C805C9F8-82AB-402E-894A-1F638FC27CD7Q43775320-27D8E0EB-BC3C-42C2-B7D5-0F4BBC1E743AQ44103468-47F8A625-7B0E-461F-9B03-AE2CDC03B203
P2860
Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Highly drug-resistant HIV-1 cl ...... current clinical development.
@en
type
label
Highly drug-resistant HIV-1 cl ...... current clinical development.
@en
prefLabel
Highly drug-resistant HIV-1 cl ...... current clinical development.
@en
P2093
P2860
P1433
P1476
Highly drug-resistant HIV-1 cl ...... current clinical development.
@en
P2093
P2860
P304
P356
10.1097/00002030-199904160-00006
P407
P577
1999-04-01T00:00:00Z